Company:  SORRENTO THERAPEUTICS, IN ... (SRNE)
Form Type:  4
Filing Date:  4/21/2017 
CIK:  0000850261 
Address:  4955 DIRECTORS PLACE 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-203-4100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.71  
Change: 
0.055 (3.33%)  
Trade Time: 
01:03 PM EST  
Market Cap: 
$130.50M
Trade SRNE now with 

© 2017  
Description of Business
Sorrento is a clinical stage biotechnology company focused on delivering clinically meaningful therapies to patients and their families, globally. Our primary focus is to transform cancer into a treatable or chronically manageable disease. We also have programs assessing the use of our technologies and products in auto-immune, inflammatory, neurodegenerative, infectious diseases and pain indications with high unmet medical needs. At our core, we are an antibody-centric company and leverage our proprietary G-MAB(TM) library to identify, screen and validate fully human antibodies against high impact oncogenic targets and mutations, immune modulators and intracellular targets. To date, we have screened over 100 validated targets and generated a number of fully human antibodies against these targets which are at various stages of preclinical development. These include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES